{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T07:45:20Z","timestamp":1769240720265,"version":"3.49.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,3,4]],"date-time":"2014-03-04T00:00:00Z","timestamp":1393891200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"funder":[{"DOI":"10.13039\/501100002426","name":"Telethon Foundation","doi-asserted-by":"publisher","award":["GGP10101"],"award-info":[{"award-number":["GGP10101"]}],"id":[{"id":"10.13039\/501100002426","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Association Fran\u00e7aise contre les Myopathies","award":["15020"],"award-info":[{"award-number":["15020"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Neurology"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.expneurol.2014.02.023","type":"journal-article","created":{"date-parts":[[2014,3,6]],"date-time":"2014-03-06T06:16:21Z","timestamp":1394086581000},"page":"96-102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"special_numbering":"C","title":["Preclinical evaluation of marketed sodium channel blockers in a rat model of myotonia discloses promising antimyotonic drugs"],"prefix":"10.1016","volume":"255","author":[{"given":"Jean-Fran\u00e7ois","family":"Desaphy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Carbonara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Costanza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Conte Camerino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.expneurol.2014.02.023_bb0005","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1113\/jphysiol.1974.sp010620","article-title":"On the repetitive discharge in myotonic muscle","volume":"240","author":"Adrian","year":"1974","journal-title":"J. Physiol."},{"key":"10.1016\/j.expneurol.2014.02.023_bb0010","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1212\/01.wnl.0000257825.29703.e8","article-title":"Efficacy of propafenone in paramyotonia congenita","volume":"68","author":"Alfonsi","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2014.02.023_bb0015","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/chir.20240","article-title":"Facile, alternative route to lubeluzole, its enantiomer, and the racemate","volume":"18","author":"Bruno","year":"2006","journal-title":"Chirality"},{"issue":"5","key":"10.1016\/j.expneurol.2014.02.023_bb0020","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/00005344-198811000-00017","article-title":"Propafenone interacts stereoselectively with beta 1- and beta 2-adrenergic receptors","volume":"12","author":"Burnett","year":"1988","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"3","key":"10.1016\/j.expneurol.2014.02.023_bb0025","doi-asserted-by":"crossref","first-page":"e784","DOI":"10.1542\/peds.2012-3065","article-title":"Diagnosis and outcome of SCN4A-related severe neonatal episodic laryngospasm (SNEL): 2 new cases","volume":"132","author":"Caietta","year":"2013","journal-title":"Pediatrics"},{"key":"10.1016\/j.expneurol.2014.02.023_bb0030","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S1566-2772(00)00011-6","article-title":"Voltage-gated ion channelopathies of the nervous system","volume":"1","author":"Cannon","year":"2001","journal-title":"Clin. Neurosci. Res."},{"key":"10.1016\/j.expneurol.2014.02.023_bb0035","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ejmech.2013.03.064","article-title":"2-Aminobenzothiazole derivatives: search for new antifungal agents","volume":"64","author":"Catalano","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.expneurol.2014.02.023_bb0040","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1085\/jgp.201210892","article-title":"Excitation-induced exchange of Na+, K+, and Cl\u2212 in rat EDL muscle in vitro and in vivo: physiology and pathophysiology","volume":"141","author":"Clausen","year":"2013","journal-title":"J. Gen. Physiol."},{"key":"10.1016\/j.expneurol.2014.02.023_bb0045","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.nurt.2007.01.013","article-title":"Ion channel pharmacology","volume":"4","author":"Conte Camerino","year":"2007","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.expneurol.2014.02.023_bb0050","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0960-8966(98)00115-1","article-title":"Effect of mexiletine on sea anemone toxin-induced non-inactivating sodium channels of rat skeletal muscle: a model of sodium channel myotonia","volume":"9","author":"Desaphy","year":"1999","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.expneurol.2014.02.023_bb0070","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1212\/WNL.57.10.1849","article-title":"Gating of myotonic Na channel mutants defines the response to mexiletine and a potent derivative","volume":"57","author":"Desaphy","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2014.02.023_bb0090","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1124\/mol.63.3.659","article-title":"Different ability of clenbuterol and salbutamol to block sodium channels predicts their therapeutic use in muscle excitability disorders","volume":"63","author":"Desaphy","year":"2003","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.expneurol.2014.02.023_bb0065","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1113\/jphysiol.2003.046995","article-title":"Different flecainide sensitivity of hNav1.4 channels and myotonic mutants explained by state-dependent block","volume":"554","author":"Desaphy","year":"2004","journal-title":"J. Physiol."},{"issue":"3","key":"10.1016\/j.expneurol.2014.02.023_bb0080","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.pain.2009.01.010","article-title":"Involvement of voltage-gated sodium channels blockade in the analgesic action of orphenadrine","volume":"142","author":"Desaphy","year":"2009","journal-title":"Pain"},{"key":"10.1016\/j.expneurol.2014.02.023_bb0075","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3389\/fphar.2012.00017","article-title":"Molecular insights into the local anesthetic receptor within voltage-gated sodium channels using hydroxylated analogs of mexiletine","volume":"3","author":"Desaphy","year":"2012","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.expneurol.2014.02.023_bb0085","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s00228-012-1414-3","article-title":"Dramatic improvement of myotonia permanens with flecainide: a two-case report of a possible bench-to-bedside pharmacogenetics strategy","volume":"69","author":"Desaphy","year":"2013","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.expneurol.2014.02.023_bb0060","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.neuropharm.2012.09.006","article-title":"In vivo evaluation of antimyotonic efficacy of \u03b2-adrenergic drugs in a rat model of myotonia","volume":"65","author":"Desaphy","year":"2013","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/j.expneurol.2014.02.023_bb0055","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1124\/mol.112.080804","article-title":"Molecular dissection of lubeluzole use-dependent block of voltage-gated sodium channels discloses new therapeutic potentials","volume":"83","author":"Desaphy","year":"2013","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.expneurol.2014.02.023_bb0095","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/281580a0","article-title":"Combined effects of adrenaline and insulin on active electrogenic Na+\u2013K+ transport in rat soleus muscle","volume":"281","author":"Flatman","year":"1976","journal-title":"Nature"},{"key":"10.1016\/j.expneurol.2014.02.023_bb0100","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1152\/jappl.1995.78.1.172","article-title":"Effect of aging on beta 2-adrenergic receptor-stimulated flux of K+, PO4, FFA, and glycerol in human forearms","volume":"78","author":"Ford","year":"1995","journal-title":"J. Appl. Physiol."},{"key":"10.1016\/j.expneurol.2014.02.023_bb0105","first-page":"CD001924","article-title":"Lubeluzole for acute ischaemic stroke","volume":"1","author":"Gandolfo","year":"2002","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.expneurol.2014.02.023_bb0110","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1111\/aas.12126","article-title":"In vitro muscle contracture investigations on the malignant hyperthermia like episodes in myotonia congenita","volume":"57","author":"Hoppe","year":"2013","journal-title":"Acta Anaesthesiol. Scand."},{"issue":"7","key":"10.1016\/j.expneurol.2014.02.023_bb0115","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1212\/WNL.0b013e3181ed9e96","article-title":"Severe neonatal episodic laryngospasm due to de novo SCN4A mutations: a new treatable disorder","volume":"75","author":"Lion-Francois","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2014.02.023_bb0120","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1212\/WNL.0b013e3181dc1a3a","article-title":"Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1","volume":"74","author":"Logigian","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2014.02.023_bb0125","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.pediatrneurol.2010.01.014","article-title":"Novel CLCN1 mutation in carbamazepine-responsive myotonia congenita","volume":"42","author":"Lyons","year":"2010","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.expneurol.2014.02.023_bb0130","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/brain\/awp294","article-title":"The non-dystrophic myotonias: molecular pathogenesis, diagnosis and treatment","volume":"133","author":"Matthews","year":"2010","journal-title":"Brain"},{"key":"10.1016\/j.expneurol.2014.02.023_bb0135","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0022-3565(25)24848-0","article-title":"Carbamazepine and 10,11-epoxycarbamazepine produce use- and voltage-dependent limitation of rapidly firing action potentials of mouse central neurons in cell culture","volume":"238","author":"McLean","year":"1986","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.expneurol.2014.02.023_bb0140","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/WCO.0b013e32833cc97e","article-title":"Skeletal muscle channelopathies: nondystrophic myotonias and periodic paralysis","volume":"23","author":"Rayan","year":"2010","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.expneurol.2014.02.023_bb0145","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1002\/ana.410420520","article-title":"A novel muscle sodium channel mutation causes painful congenital myotonia","volume":"42","author":"Rosenfeld","year":"1997","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.expneurol.2014.02.023_bb0150","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/BF02758569","article-title":"Myotonia congenita \u2014 a successful response to carbamazepine","volume":"73","author":"Savitha","year":"2006","journal-title":"Indian J. Pediatr."},{"issue":"2","key":"10.1016\/j.expneurol.2014.02.023_bb0155","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000115546","article-title":"Carbamazepine versus diphenylhydantoin in the treatment of myotonia","volume":"22","author":"Sechi","year":"1983","journal-title":"Eur. Neurol."},{"issue":"13","key":"10.1016\/j.expneurol.2014.02.023_bb0160","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1001\/jama.2012.12607","article-title":"Mexiletine for symptoms and signs of myotonia in nondystrophic myotonia: a randomized controlled trial","volume":"308","author":"Statland","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.expneurol.2014.02.023_bb0165","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1093\/brain\/awt133","article-title":"Non-dystrophic myotonia: prospective study of objective and patient reported outcomes","volume":"136","author":"Trivedi","year":"2013","journal-title":"Brain"},{"key":"10.1016\/j.expneurol.2014.02.023_bb0170","article-title":"Nondystrophic myotonia: challenges and future directions","author":"Trivedi","year":"2013","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2014.02.023_bb0175","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1113\/jphysiol.2003.054973","article-title":"Mexiletine block of wild-type and inactivation-deficient human skeletal muscle hNav1.4 Na+ channels","volume":"554","author":"Wang","year":"2004","journal-title":"J. Physiol."},{"key":"10.1016\/j.expneurol.2014.02.023_bb0180","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/s002130050524","article-title":"An active metabolite of carbamazepine, carbamazepine-10,11-epoxide, inhibits ion channel-mediated catecholamine secretion in cultures bovine adrenal medullary cells","volume":"135","author":"Yoshimura","year":"1998","journal-title":"Psychopharmacology"}],"container-title":["Experimental Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488614000752?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488614000752?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:19:18Z","timestamp":1746145158000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014488614000752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":36,"alternative-id":["S0014488614000752"],"URL":"https:\/\/doi.org\/10.1016\/j.expneurol.2014.02.023","relation":{},"ISSN":["0014-4886"],"issn-type":[{"value":"0014-4886","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical evaluation of marketed sodium channel blockers in a rat model of myotonia discloses promising antimyotonic drugs","name":"articletitle","label":"Article Title"},{"value":"Experimental Neurology","name":"journaltitle","label":"Journal Title"},{"value":"http:\/\/dx.doi.org\/10.1016\/j.expneurol.2014.02.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}